Abstract
Updated results from the ongoing phase III CROWN study (NCT03052608) confirmed the durable systemic and intracranial (IC) benefit of lorlatinib (LOR), a 3rd generation anaplastic lymphoma kinase (ALK) inhibitor, vs crizotinib (CRIZ) in patients (pts) with treatment-naive ALK-positive non-small cell lung cancer. The 3-year follow up evaluated long-term IC safety and efficacy of LOR (data cutoff 20 September 2021).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
